Botulinum Toxin Market Size Analysis and Top Companies
The global botulinum toxin market size is estimated to hit around USD 19.68 billion by 2033 from USD 8.65 billion in 2024, with a CAGR of 9.57% from 2024 to 2033. The top companies operating in the botulinum toxin market are Eisai Co., Ltd, Evolus, Inc., Galderma laboratories., HUGEL, Inc., Hugh Source Ltd., Ipsen Pharma, Lanzhou Institute of Biological Products Co., Ltd., Medy-Tox, Inc., Merz Pharma GmbH & Co. KGaA, Metabiologics, Inc., Pfizer Inc, Revance Therapeutics, Inc., Teijin Pharma Ltd, US WorldMeds, LLC and others.
Botulinum Toxin Market Scope
| Report Coverage |
Details |
| Market Size in 2024 |
USD 8.65 Billion |
| Market Size by 2034 |
USD 21.57 Billion |
| Growth Rate from 2024 to 2034 |
CAGR of 9.56% |
| Base Year |
2023 |
| Forecast Period |
2024 to 2034 |
| Segments Covered |
By Product Type, By Application, and By End-Use |
| Regions Covered |
North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Botulinum Toxin Market Companies
- Eisai Co., Ltd
- Evolus, Inc.,
- Galderma laboratories.
- HUGEL, Inc. (Korea)
- Hugh Source (International) Ltd.
- Ipsen Pharma
- Lanzhou Institute of Biological Products Co., Ltd. (China)
- Medy-Tox, Inc.
- Merz Pharma GmbH & Co. KGaA
- Metabiologics, Inc.
- Pfizer Inc
- Revance Therapeutics, Inc. (U.S.)
- Teijin Pharma Ltd
- US WorldMeds, LLC
Recent Developments
- In Nov 2021, Evolus Inc. declared that it has begun a preclinical study to examine an extra helping of the wrinkle-treatment drug Jeuveau (pra botulinum toxin A-xv) for a longer period. This should allow the corporation to improve how its product is applied to different medical situations.
- Tenjin Pharma's Xeomin (into botulinum toxin A) with intravenous infusion in 50, 100, and 200 doses for the therapy of lower extremity spasticity was approved by the Japanese Ministry of Health and will be sold by Merz Pharmaceuticals and Tenjin Medicine beginning in July 2020. With the help of this strategy, the company will be able to boost its income production stream by adding value to its business portfolio.
- In July 2020, the USFDA approved Allergan's additional biopharma permit application, allowing BOTOX to know to be used to treat stiffness in children 2 years of age and older. The proposal also mentions using BOTOX to treat kids with cerebral palsy-related lower limb stiffness.
- At the premier symposium on neurotoxins in July 2022, Swiss firm Fastox Pharma revealed their ground-breaking lengthy botulinum toxin LAST innovation. Botulinum types A (BoNT/A) and incredibly quickly myorelaxant medications have been found to enhance each other's effects, according to Fastox.
- Aquavit Holdings LLC obtained an exclusive license in April 2021 for the registration, commercialization, and marketing of its botulinum (DTX-021) within Canada and the United States.
We have prepared a service to support you. please feel free to contact us at sales@precedenceresearch.com | +1 804 441 9344
